Zyus Life Sciences posts positive topline Phase 2a UTOPIA-1 results for Trichomylin in advanced cancer pain

• Zyus Life Sciences reported positive topline results from its Phase 2a UTOPIA-1 trial of Trichomylin for advanced cancer pain.
• The small signal-finding study supported tolerability, showed pain relief signals, suggested improved quality of life, suggested reduced opioid use.
• Topline results will be presented at the Montreal International Palliative Care Congress in October 2026.
• Results support moving into larger randomized trials, with opioid reduction planned as a co-primary endpoint alongside pain efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyus Life Sciences Corporation published the original content used to generate this news brief via CNW (Ref. ID: 202610010809CANADANWCANADAPR_C1504) on October 01, 2026, and is solely responsible for the information contained therein.